Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that Dr. Kyle Dempsey has been...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces that Gilbert Godin, CEO, and Tim...
Q3 2022 revenue of $15.7 million, Adjusted EBITDA of $6.0 million and cash from operations of $4.2 million. Total Vascepa prescriptions grew 14% sequentially and 89% year-over-year. 2,800...
Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore Cardiovascular Risk Reduction Benefits of Eicosapentaenoic Acid ("EPA") for Patients TORONTO, Nov. 7, 2022 /CNW/ - HLS...
HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), announces that it will release its Q3 Fiscal 2022 financial results on Thursday, November 10, 2022. The Company will hold a conference...